COMPARATIVE PHARMACOECONOMIC ANALYSIS OF LONG-ACTING LANREOTIDE USED IN ACROMEGALY THERAPY WITHIN CONDITIONS OF THE RUSSIAN FEDERATION HEALTH CARE SYSTEM

Author:

Krysanov I. S.1ORCID,Makarova E. V.2ORCID,Ermakova V. Yu.3ORCID

Affiliation:

1. 1.Moscow State University of Food Production 2. LLC “Institute of Clinical and Economic Expertise and Pharmacoeconomics” 3. A.I. Yevdokimov Moscow State University of Medicine and Dentistry

2. 1. A.I. Yevdokimov Moscow State University of Medicine and Dentistry 2. National Scientific Research Institute of Public Health

3. 1. LLC “Institute of Clinical and Economic Expertise and Pharmacoeconomics” 2. Sechenov First Moscow State Medical University

Abstract

The aim of this study is to conduct a comprehensive pharmacoeconomic evaluation of the use of long-acting subcutaneous lanreotide gel compared to alternative drugs, for the treatment of acromegaly.Materials and methods. Based on the literature data, a treatment model with a 1-year outlook was developed, a cost-effectiveness analysis (CEA) in pharmacoeconomics and a sensitivity analysis of changes in the model parameters were carried out. Direct medical costs for the annual therapy course were calculated. The data on the medicines costs were taken from the register of marginal prices of the State Register of Medicines.Results. According to the unified Russian registry of the pituitary-hypothalamic tumors area, the achievement of remission in the acromegaly patients using lanreotide, a long-acting gel for a subcutaneous administration, compared to the long-acting octreotide, is 51% vs 24%. During the first year of treatment with octreotide, the total pharmacotherapy costs were lower than with lanreotide (RUB 225,496.07 vs RUB 574,451.84). According to the results of the cost-effectiveness analysis for one achieved case of remission, the advantage of using lanreotide over long-acting octreotide was revealed (RUB 1,251,870.56 versus RUB 1,431,005.31). The sensitivity analysis demonstrated the model’s stability to increases in the lanreotide price (up to +18%), decreases in the octreotide prices (up to –22%), increases in the transsphenoidal adenomectomy prices (up to +59%), and decreased lanreotide remission rates (up to –12%).Conclusion. Although the treatment costs analysis showed lower total per year costs of the treatment with long-acting octreotide compared to lanreotide, the calculation of the cost-effectiveness ratio per remission showed that lanreotide had been superior to long-acting octreotide.

Publisher

Volgograd State Medical University

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,Pharmacy

Reference29 articles.

1. Dedov II, Molitvoslovova NN, Rozhinskaia LI, Mel’nichenko GA. Russian association of endocrinologists national practice guidelines (clinical signs, diagnosis, differential diagnosis, treatment). Acromegaly. Problems of Endocrinology. 2013;59(6):4–18. DOI: 10.14341/probl20135964-18. Russian

2. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Hassan MM, Utz A, Wass JAH. Acromegaly: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2014; 99(11):3933–51. DOI: 10.1210/jc.2014-2700.

3. Belaya ZE, Golounina OO, Rozhinskaya LY, Melnichenko GA, Isakov MА, Lutsenko AS, Alekseeva T, Zenkova TS, Przhiyalkovskaya EG, Panyushkina GM, Ilukhina OB, Ivanova EI, Krishtal EA, Vachygova AA, Pigarova EA, Dzeranova LK, Marova EI, Arpova SD, Mamedova EO, Grebennikova TA, Antsiferov MB, Dreval AV, Dedov II. Epidemiology, clinical manifestations and efficiency of different methods of treatment of acromegaly according to the United Russian Registry of Patients with Pituitary Tumors.Problems of Endocrinology. 2020;66(1):93–103. DOI: 10.14341/probl10333. Russian

4. Golounina OO, Dzeranova LK, Pigarova EA, Belaya ZE. Resistance to drug treatment of acromegaly and ways to overcome it. Obesity and metabolism. 2021;18(2):150–62. DOI: 10.14341/omet12710. Russian

5. Dreval AV, Pokramovich YuG, Tishenina RS. The effectiveness of analysis of octreotide-depo, a long-acting somatostatin analog, for the treatment of the patients presenting with active phase of acromegalia. Problems of Endocrinology. 2014;60(3):10–4. DOI: 10.14341/probl201460310-14. Russian

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3